Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1986 Feb;45(2):101–109. doi: 10.1136/ard.45.2.101

Cultured human cells with high levels of gold-binding cytosolic metallothionein are not resistant to the growth inhibitory effect of sodium aurothiomalate.

A Glennås, H E Rugstad
PMCID: PMC1001828  PMID: 3080971

Abstract

We have previously shown that cells with a high content of the gold-binding protein metallothionein (MT) are resistant to the growth inhibitory effects of gold(III) chloride and auranofin. To investigate whether MT confers resistance to sodium aurothiomalate two cell lines of cultured human epithelial (HE) cells were used; the parental cell line (HE) and a substrain (HE100) containing high levels of cytosolic MT. Sodium aurothiomalate and thiomalic acid without gold both caused a dose-dependent growth inhibition of both cell lines when used in the concentration range 25-300 mumol/l culture medium and for four days' exposure. MT, despite binding about one third of the cytosolic gold, did not protect against the antiproliferative effect of sodium aurothiomalate. The gold and the thiomalate moieties were distributed differently within the cells; 30% of the cellular gold and 80% of the thiomalate were recovered in the cytosol. Gold was mainly protein bound in both cell lines, as shown by G75 Sephadex gel filtration of the cytosols. In the HE100 cells about 30% of the gold eluted with MT. The thiomalate eluted mainly with substances with molecular weights less than 1000. Cellular synthesis of MT was not observed during sodium aurothiomalate treatment. The results indicate that the sodium aurothiomalate molecule dissociates and support the suggestion that the thiomalate moiety is, in part, responsible for the antiproliferative effect of the drug.

Full text

PDF
101

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bakka A., Endresen L., Johnsen A. B., Edminson P. D., Rugstad H. E. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol. 1981 Nov;61(2):215–226. doi: 10.1016/0041-008x(81)90411-7. [DOI] [PubMed] [Google Scholar]
  2. Endresen L., Thorsrud A. K., Jellum E., Willard-Gallo K. E., Rugstad H. E. Protein mapping of two metallothionein-rich cell strains and their parent lines, using high-resolution two-dimensional electrophoresis. Anal Biochem. 1984 Nov 15;143(1):170–178. doi: 10.1016/0003-2697(84)90573-6. [DOI] [PubMed] [Google Scholar]
  3. Glennås A., Bakka A., Rugstad H. E. Cultured human cells with a high content of metallothionein show resistance against gold-chloride. Scand J Rheumatol. 1983;12(4):321–324. doi: 10.3109/03009748309099734. [DOI] [PubMed] [Google Scholar]
  4. Gottlieb N. L. Comparative pharmacokinetics of parenteral and oral gold compounds. J Rheumatol Suppl. 1982 Jul-Aug;8:99–109. [PubMed] [Google Scholar]
  5. Houpt J. B., Alpert B., Lotem M., Greyson N. D., Pritzker K. P., Langer F., Gross A. E. Spontaneous osteonecrosis of the medial tibial plateau. J Rheumatol. 1982 Jan-Feb;9(1):81–90. [PubMed] [Google Scholar]
  6. Jellum E., Munthe E. Fate of the thiomalate part after intramuscular administration of aurothiomalate in rheumatoid arthritis. Ann Rheum Dis. 1982 Aug;41(4):431–432. doi: 10.1136/ard.41.4.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jellum E., Munthe E., Guldal G., Aaseth J. Fate of the gold and the thiomalate part after intramuscular administration of aurothiomalate to mice. Ann Rheum Dis. 1980 Apr;39(2):155–158. doi: 10.1136/ard.39.2.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jellum E., Munthe E., Guldal G., Aaseth J. Gold and thiol compounds in the treatment of rheumatoid arthritis: excretory fate and tissue distribution of thiomalate in relation to gold after administration of myocrisin (auro-thiomalate). Scand J Rheumatol Suppl. 1979;(28):28–36. [PubMed] [Google Scholar]
  9. Mogilnicka E. M., Webb M. Comparative studies on the distribution of gold, copper and zinc in the livers and kidneys of rats and hamsters after treatment with sodium [195Au]-aurothiomalate. J Appl Toxicol. 1981 Dec;1(6):287–291. doi: 10.1002/jat.2550010602. [DOI] [PubMed] [Google Scholar]
  10. Mogilnicka E. M., Webb M. The effects of cadmium and copper on the renal uptake and metallothionein binding of gold in the rat and hamster. Chem Biol Interact. 1982 Jun;40(2):247–256. doi: 10.1016/0009-2797(82)90104-1. [DOI] [PubMed] [Google Scholar]
  11. Payne B. J., Walz D. T. The toxicity of three gold compounds in laboratory animals. Vet Pathol Suppl. 1978 Aug;15(5):1–3. [PubMed] [Google Scholar]
  12. Ree K., Johnsen A. S., Rugstad H. E., Bakka A., Hovig T. Characterization of a human epithelial cell line with special reference to its ultrastructure. Acta Pathol Microbiol Scand A. 1981 Mar;89(2):73–80. doi: 10.1111/j.1699-0463.1981.tb00192.x. [DOI] [PubMed] [Google Scholar]
  13. Rudge S. R., Perrett D., Swannell A. J. Free thiomalate in plasma and urine of patients receiving sodium aurothiomalate. Ann Rheum Dis. 1984 Feb;43(1):66–69. doi: 10.1136/ard.43.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rugstad N. E., Norseth T. Cadmium resistance and content of cadmium-binding protein in cultured human cells. Nature. 1975 Sep 11;257(5522):136–137. doi: 10.1038/257136a0. [DOI] [PubMed] [Google Scholar]
  15. Sharma R. P., McQueen E. G. The binding of gold to cytosolic proteins of the rat liver and kidney tissues: metallothioneins. Biochem Pharmacol. 1980 Jul 15;29(14):2017–2021. doi: 10.1016/0006-2952(80)90486-4. [DOI] [PubMed] [Google Scholar]
  16. Talamantes F., Ogren L., Markoff E., Woodard S., Madrid J. Phylogenetic distribution, regulation of secretion, and prolactin-like effects of placental lactogens. Fed Proc. 1980 Jun;39(8):2582–2587. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES